AskGene Will Give an Oral Presentation on the Latest Clinical Results for ASKB589 at IGGC 2023

/in /by

Camarillo, California, June 2, 2023 – AskGene Pharma Inc. is pleased to announce its participation in the prestigious 15th International Gastric Cancer Congress (IGCC 2023), scheduled to take place on June 14-17, 2023 in Yokohama, Japan. At the conference, AskGene will give an oral presentation on the latest clinical results of NCT04632108 for ASKB589, an anti-CLDN18.2 antibody, on June 16, 2023. The presenter will be the leading principal investigator Dr. Lin Shen, professor from Peking University Cancer Hospital.

IGCC is a world renowned biennial global academic conference sponsored by the International Gastric Cancer Association (IGCA). IGCC 2023 will be a hybrid online/offline conference.

Presentation Details

  • Title: A phase I/II study of ASKB589 (Anti-Claudin 18.2 (CLDN18.2) monoclonal antibody) in patients with solid tumors
  • Session: Oral 26 – Clinical Study
  • Date and Time: Friday, June 16, 2023 16:50-17:22 Local Time
  • Abstract Number: 01074
  • Leading PI: Dr. Lin Shen, professor from Peking University Cancer Hospital.

About NCT04632108

The NCT04632108 study is a first-in-human study evaluating the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of ASKB589 as a monotherapy and in a combination chemotherapy in patients with advanced solid tumors. The study includes ASKB589 monotherapy dose escalation and expansion (Part A) and dose escalation and expansion of ASKB589 combined with CAPOX (capecitabine and oxaliplatin) (Part B). Patients in the dose escalation were enrolled regardless of the expression of CLDN18.2, while patients in the dose expansion were only enrolled if their tumors tested positive for CLDN18.2 by a central laboratory assay. Enrollment in dose escalation for ASKB589 as monotherapy and in combination with CAPOX chemotherapy was completed in 2022. Enrollment continues in expansion cohorts of first-line advanced or metastatic patients with CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma that is being treated with ASKB589 in combination with chemotherapy.

About ASKB589

ASKB589 is an innovative biological drug discovered and developed by AskGene. It is a recombinant humanized monoclonal antibody targeting claudin 18.2. The drug mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) through high-affinity binding to cancer cells. In addition to gastric and gastroesophageal junction cancers, ASKB589 is being tested in clinical trials for other CLDN18.2-positive solid tumors such as pancreatic cancer. A pivotal Phase III study of ASKB589 in the treatment of gastric cancer is being planned.

About AskGene Pharma

AskGene Pharma, founded in 2012 in Los Angeles, California, is dedicated to the discovery and development of novel antibody and fusion protein therapeutics. It has established the proprietary SmartKine® cytokine prodrug platform, which significantly improves the developability of cytokines for oncology and inflammation indications. AskGene has multiple programs in clinical and preclinical developments. In addition to the first-in-class cytokine prodrug programs in clinical state, AskGene is actively advancing several programs with the potential of being best-in-class into late-stage clinical development, including a pivotal clinical study of ASKB589 and a clinical study of ASKG712, a dual-targeting antibody for the treatment of ophthalmology indications.

Forward-looking statement Disclaimer

This website contains forward-looking statements that involve risks, uncertainties and assumptions. These forward-looking statements reflect the Company’s views at the time such statement was made with respect to future events and are not a guarantee of future performance or developments. All statements other than statements of historical fact may be deemed as forward-looking, including but not limited to: any statements regarding plans, strategies and objectives for the future management of operations, including but not limited to, our clinical development and commercialization plans; predictions of any financial information; any statement of historical results that may indicate trends in our business development; statements of any expectations or beliefs regarding future events, potential markets or market size, technological developments, product lines, clinical data, results, experiments or their implications, enforceability of intellectual property rights, competitive advantage or our position in the industry; and any hypothetical statements of the items mentioned.